MEDIPOST announced that its stem cell-based Alzheimer’s disease drug, ‘NEUROSTEM®’ has been approved by FDA for clinical trials.
With this approval, MEDIPOST can now conduct Phase 1 and 2a clinical trials on patients with mild to moderate Alzheimer’s Disease to examine NEUROSTEM®’s safety and exploratory efficacy.
The clinical trials will involve repeated administrations of three NEUROSTEM®s in 9 to 18 patients.
According to non-clinical animal tests conducted in Korea, ‘NEUROSTEM®’ was found to 1) reduce amyloid β-proteins, 2) inhibit hyperphosphorylation and cohesion of tau protein, 3) inhibit destruction of nerve cells, 4) restore synaptic function and affect causative agents and pathological features of Alzheimer’s disease in multiple ways.
MEDIPOST also expects that NEUROSTEM® can help neural progenitors in brain to be divided into nerve cells and ultimately lead to preventing and treating Alzheimer’s disease by inducing nerve regeneration.